Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.
about
Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature reviewClinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.Consensus on biomarkers for neuroendocrine tumour diseaseA Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementFollow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians.Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.Using a Delphi process to determine optimal care for patients with pancreatic cancer.Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report.Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and mythsCarcinoid abdominal crisis: a case reportSomatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells
P2860
Q26866246-5800B454-7382-4670-9A78-A14118A71647Q34127873-3012C7C5-72BC-43A3-B470-20B190AB6AB2Q35128224-36A0F4C1-7714-474C-B088-ADB683CDF003Q37255681-5BC137CA-F4D1-40F4-A3C6-D27A3C8F541FQ37302087-687BD30D-7C7A-4054-9E8A-A5ED97869928Q46644513-2BACA6EE-7973-4006-AA63-2A0BEE650001Q47094179-58982042-A0D0-416A-8175-5B8188ED688EQ48878943-AAC45A8A-137C-4E4E-9CC4-30347D90578DQ50048308-FD386669-408F-446D-A82A-9511030CDD39Q55502689-F65B827C-C88A-49A9-BC07-F965EB5B3C29Q56962802-FFACE761-EE86-43FF-843F-ACD2A5EAC0DBQ57109528-DF15949C-290C-42D9-B8C3-CB955E82F260Q57679679-DCE491D5-883D-4D9E-8AC4-ADB0CA1F52AE
P2860
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systemic treatment in unresect ...... rom a modified delphi process.
@en
type
label
Systemic treatment in unresect ...... rom a modified delphi process.
@en
prefLabel
Systemic treatment in unresect ...... rom a modified delphi process.
@en
P2093
P1433
P1476
Systemic treatment in unresect ...... rom a modified delphi process.
@en
P2093
Al B Benson
Bulent Arslan
Dasha Cherepanov
Edward Greeno
Edward M Wolin
GEPNET Treatment Consensus Panel
George A Fisher
Jennifer L Malin
John F Gibbs
Jonathan R Strosberg
P304
P356
10.1097/MPA.0B013E31826D3A17
P577
2013-04-01T00:00:00Z